Aspire’s sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing TxB2 is a biomarker indicating aspirin’s effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage Lab results showed Aspire’s product acted approximately twice as fast as…

You can read the full content here